mocetinostat mocetinostat mocetinostat (mgcd0103) is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers including follicular lymphoma, hodgkin's lymphoma and acute myelogenous leukemia. mocetinostat names preferred iupac name n-(2-aminophenyl)-4-(methyl)benzamide identifiers cas number 726169-73-9 y 3d model (jsmol) interactive image chembl chembl272980 n chemspider 8041206 n iuphar/bps 7008 kegg d09641 pubchem cid 9865515 unii a6gwb8t96j y comptox dashboard (epa) dtxsid80222945 inchi inchi=1s/c23h20n6o/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15h,14,24h2,(h,28,30)(h,26,27,29) nkey: hrnlubsxihfdhp-uhfffaoysa-n ninchi=1/c23h20n6o/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15h,14,24h2,(h,28,30)(h,26,27,29)key: hrnlubsxihfdhp-uhfffaoyaw smiles c1=cc=c(c(=c1)n)nc(=o)c2=cc=c(c=c2)cnc3=nc=cc(=n3)c4=cn=cc=c4 properties chemical formula c23h20n6o molar mass 396.454 g·mol−1 except where otherwise noted, data are given for materials in their standard state (at 25 °c , 100 kpa). n verify (what is yn ?) infobox references one clinical trial (for refractory follicular lymphoma) was temporarily put on hold due to cardiac problems but resumed recruiting in 2009. in 2010 favourable results were announced from the phase ii trial for hodgkin's lymphoma. mgcd0103 has also been used as a research reagent where blockage of members of the hdac-family of histone deacetylases is required. mechanism of action it works by inhibiting mainly histone deacetylase 1 (hdac1), but also hdac2, hdac3, and hdac11.